AffiliationUniv Arizona, Biomed Corp Alliances
Univ Arizona, Hlth Sci
Univ Arizona, Precis Hlth Sci
Univ Arizona, Ctr Appl Genet & Genom Med
MetadataShow full item record
PublisherLIPPINCOTT WILLIAMS & WILKINS
CitationSilva, P. J., & Ramos, K. S. (2018). Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh–Dole Act. Academic Medicine, 93(8), 1135-1141. doi: 10.1097/ACM.0000000000002259
Rights© 2018 by the Association of American Medical Colleges.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractInnovation ecosystems tied to academic medical centers (AMCs) are inextricably linked to policy, practices, and infrastructure resulting from the Bayh-Dole Act in 1980. Bayh-Dole smoothed the way to patenting and licensing new drugs and, to some degree, medical devices and diagnostic reagents. Property rights under Bayh-Dole provided significant incentive for industry investments in clinical trials, clinical validation, and industrial scale-up of products that advanced health care. Bayh-Dole amplified private investment in biotechnology drug development and, from the authors' perspective, did not significantly interfere with the ability of AMCs to produce excellent peer-reviewed science. In today's policy environment, it is increasingly difficult to patent and license products based on the laws of natureas the scope of patentability has been narrowed by case law and development of a suitable clinical and business case for the technology is increasingly a gating consideration for licensees. Consequently, fewer academic patents are commercially valuable. The role of technology transfer organizations in engaging industry partners has thus become increasingly complex. The partnering toolbox and organizational mandate for commercialization must evolve toward novel collaborative models that exploit opportunities for future patent creation (early drug discovery), data exchange (precision medicine using big data), cohort assembly (clinical trials), and decision rule validation (clinical trials). These inputs contribute to intellectual property rights, and their clinical exploitation manifests the commercialization of translational science. New collaboration models between AMCs and industry must be established to leverage the assets within AMCs that industry partners deem valuable.
Note12 month embargo; published online: 01 August 2018
VersionFinal accepted manuscript
SponsorsUniversity of Arizona
- Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
- Authors: Colaianni A, Cook-Deegan R
- Issue date: 2009 Sep
- University-based science and biotechnology products: defining the boundaries of intellectual property.
- Authors: Kesselheim AS, Avorn J
- Issue date: 2005 Feb 16
- Academic medical centers as innovation ecosystems to address population -omics challenges in precision medicine.
- Authors: Silva PJ, Schaibley VM, Ramos KS
- Issue date: 2018 Feb 15
- Bayh-Dole: if we knew then what we know now.
- Authors: Boettiger S, Bennett AB
- Issue date: 2006 Mar
- The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms.
- Authors: Sarpatwari A, Kesselheim AS, Cook-Deegan R
- Issue date: 2022 Dec 1